The inquiry centers on the timeline for Revtorpyk, the company’s recently approved breast cancer treatment. While Celcuity secured FDA approval for the drug on July 14, 2026, the company’s subsequent guidance indicating a late third-quarter launch caught analysts off guard. Market observers, including Stifel analyst Stephen Wiley and Leerink’s Andrew Berens, highlighted that the timeline appeared extended compared to previous expectations regarding the firm's launch readiness.

Investors reacted sharply to the disclosure, driving the stock down $19.54 to close at $91.51 on July 15, 2026. Pomerantz LLP is currently inviting shareholders who suffered losses to contact Danielle Peyton at 646-581-9980 to discuss potential class action participation.